Splenic iron decreases without change in volume or liver parameters during luspatercept therapy
- 30 November 2023
- journal article
- research article
- Published by American Society of Hematology in Blood
- Vol. 142 (22) , 1932-1934
Abstract
Splenic iron decreased whereas liver iron was stable during luspatercept therapy in some individuals with thalassemia. This suggests a reduction of ineffective erythropoiesis changes the organ distribution of iron and demonstrates that liver iron concentration alone may not accurately reflect total body iron content. This article describes data from subjects enrolled in BELIEVE (NCT02604433) and BEYOND (NCT03342404).Keywords
This publication has 16 references indexed in Scilit:
- A Phase 3 Trial of Luspatercept in Patients with Transfusion-Dependent β-ThalassemiaNew England Journal of Medicine, 2020
- The Efficacy of Iron Chelators for Removing Iron from Specific Brain Regions and the Pituitary—Ironing out the BrainPharmaceuticals, 2019
- Iron metabolism under conditions of ineffective erythropoiesis in β-thalassemiaBlood, 2019
- Physiology and pathophysiology of iron in hemoglobin-associated diseasesFree Radical Biology and Medicine, 2014
- Relaxivity‐iron calibration in hepatic iron overload: Probing underlying biophysical mechanisms using a Monte Carlo modelMagnetic Resonance in Medicine, 2010
- Hepcidin in β‐thalassemiaAnnals of the New York Academy of Sciences, 2010
- The Role of Hepcidin in Iron MetabolismActa Haematologica, 2009
- Spleen R2 and R2* in iron‐overloaded patients with sickle cell disease and thalassemia majorJournal of Magnetic Resonance Imaging, 2009
- MRI R2 and R2* mapping accurately estimates hepatic iron concentration in transfusion-dependent thalassemia and sickle cell disease patientsBlood, 2005
- Hepatic Iron Concentration and Total Body Iron Stores in Thalassemia MajorNew England Journal of Medicine, 2000